Secondary outcomes (variables not normally distributed)
| Intervention | Comparison | p Value | ||
|---|---|---|---|---|
| EQ-5D health utility (continuous, 0.000=dead; 1.000 perfect health) | ||||
| Baseline | Median (IQR) | 0.848 (0.725, 1.000) | 0.796 (0.620, 1.000) | |
| Follow-up | Median (IQR) | 1.000 (0.796, 1.000) | 0.796 (0.727, 1.000) | |
| Change | Median (IQR) | 0.000 (0.000, 0.111) | 0.0000 (−0.052, 0.194) | 0.972 |
| EQ-5D visual analogue scale (continuous, 0 worst health; 100 best health) | ||||
| Baseline | Median (IQR) | 75 (70, 84) | 80 (70, 90) | |
| Follow-up | Median (IQR) | 80 (73, 88) | 80 (70, 90) | |
| Change | Median (IQR) | 2.5 (−6.5, 13.0) | 1.0 (−10, 10) | 0.409 |
| FeNO (continuous, low score indicates low inflammation) | ||||
| Baseline | Median (IQR) | 26.0 (16.0, 46.5) | 25.0 (11.0, 36.0) | |
| Follow-up | Median (IQR) | 23.0 (12.0, 44.5) | 19.0 (10.0, 27.0) | |
| Change | Median (IQR) | −2.5 (−11.5, 8.5) | −2.0 (−15.0, 2.0) | 0.615 |
| Puffs reliever taken per average week(continuous) | ||||
| Baseline | Median (IQR) | 11 (7, 28) | 4 (2, 12) | |
| Follow-up | Median (IQR) | 5 (0.5, 14) | 4 (0, 28) | |
| Change | Median (IQR) | −7 (−14, 1) | 0 (−4, 4) | 0.022 |
| Percentage prescribed ICS reportedly taken (continuous) | ||||
| Baseline | Median (IQR) | 85.7 (14.3, 100.0) | 100.0 (71.4, 100.0) | |
| Follow-up | Median (IQR) | 92.9 (71.4, 100.0) | 100.0 (85.7, 100.0) | |
| Change | Median (IQR) | 0.0 (0.0, 14.3) | 0.0 (0.0, 7.1) | 0.730 |
| Equivalent beclometasone dose (μg) (continuous) | ||||
| Baseline | Median (IQR) | 400 (300, 1000) | 800 (400, 800) | |
| Follow-up | Median (IQR) | 400 (300, 1000) | 800 (400, 800) | |
| Change | Median (IQR) | 0 (0, 0) | 0 (0, 0) | 0.209 |
| Prednisolone course | n (%) with at least one | 1 (5) | 3 (12) | 0.617 |
| Hospital/A&E visit | n (%) with at least one | 0 | 0 | – |
| Non-routine GP/nurse visit | n (%) with at least one | 3 (15) | 6 (24) | 0.710 |
| Routine GP/nurse visit (eg, asthma review) | n (%) with at least one | 5 (25) | 8 (32) | 0.745 |
Summaries of scores at baseline, follow-up and change from baseline. Summaries of prescribing and health service use over the study period, with Fisher's exact test for categorical data, and Mann-Whitney test to compare median differences between groups.
p Values in bold indicate significance <0.05.
A&E, accident and emergency; ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; EQ-5D, EuroQol; FeNO, fractional exhaled nitric oxide; GP, general practitioner; ICS, inhaled corticosteroids.